These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16965332)

  • 1. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367).
    Hegele RA; Ur E; Ransom TP; Cao H
    Clin Genet; 2006 Oct; 70(4):360-2. PubMed ID: 16965332
    [No Abstract]   [Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
    Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
    J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
    Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
    Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
    Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
    Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel
    Zhou L; Li S; Ren J; Wang D; Yu R; Zhao Y; Zhang Q; Xiao X
    Am J Physiol Endocrinol Metab; 2024 Sep; 327(3):E357-E370. PubMed ID: 39017680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
    Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
    Chen X; Ma Z; Chen P; Song X; Li W; Yu X; Xie J
    Front Endocrinol (Lausanne); 2022; 13():830708. PubMed ID: 35422762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical link between peroxisome proliferator-activated receptor γ and the renin-angiotensin system.
    Sigmund CD
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):676-8. PubMed ID: 23486770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).
    Lanktree M; Cao H; Rabkin SW; Hanna A; Hegele RA
    Clin Genet; 2007 Feb; 71(2):183-6. PubMed ID: 17250669
    [No Abstract]   [Full Text] [Related]  

  • 13. Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.
    Soares RMV; da Silva MA; Campos JTAM; Lima JG
    Front Endocrinol (Lausanne); 2024; 15():1394102. PubMed ID: 39398333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial partial lipodystrophy type 3: a new mutation on the PPARG gene.
    Lau E; Carvalho D; Oliveira J; Fernandes S; Freitas P
    Hormones (Athens); 2015; 14(2):317-20. PubMed ID: 26158656
    [No Abstract]   [Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
    Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
    J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
    Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
    Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
    Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
    Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.
    Broekema MF; Savage DB; Monajemi H; Kalkhoven E
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 May; 1864(5):715-732. PubMed ID: 30742913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
    Francis GA; Li G; Casey R; Wang J; Cao H; Leff T; Hegele RA
    BMC Med Genet; 2006 Jan; 7():3. PubMed ID: 16412238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.